The effects of orlistat on metabolic parameters and other cardiovascular risk factors. (Q36085597)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15803108%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

review article

1 reference

title

The effects of orlistat on metabolic parameters and other cardiovascular risk factors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15803108%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

author

Theodosios D. Filippatos

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15803108%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Moses Elisaf

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15803108%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

author name string

D N Kiortsis

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15803108%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

publication date

1 February 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15803108%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

published in

Diabetes and Metabolism

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15803108%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15803108%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

page(s)

15-22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15803108%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15803108%20AND%20SRC:MED&resulttype=core&format=json

Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers

10 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Orlistat: its current status as an anti-obesity drug

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Orlistat in the long-term treatment of obesity in primary care settings

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with Type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Administration of orlistat in a patient with familial hyperchylomicronemia

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Combination of gemfibrozil and orlistat for treatment of combined hyperlipidemia with predominant hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Usefulness of Orlistat in the treatment of severe hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Orlistat inhibits dietary cholesterol absorption

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Cardiovascular risk associated with the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

The Metabolic Syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Lipoprotein A levels after intestinal bypass operation for morbid obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Obesity, haemostasis and the fibrinolytic system

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Effects of short-term energy restriction and physical training on haemostatic risk factors for coronary heart disease in obese children and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Weight change and blood coagulability and fibrinolysis in healthy obese women

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Inflammation: the link between insulin resistance, obesity and diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Raised interleukin-6 levels in obese patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Decreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

Short-term orlistat treatment does not affect mineral balance and bone turnover in obese men.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

The Effect of Short-Term (21-Day) Orlistat Treatment on the Physiologic Balance of Six Selected Macrominerals and Microminerals in Obese Adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970161-1

7 January 2021

10.1016/S1262-3636(07)70161-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15803108%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference